The fact that FR-β—apart from being a cellular rather than a metabolic marker—is only expressed on activated macrophages in disease states such as inflammatory disorders or malignancies, supports 18F-AzaFol as a more specific alternative to [18F]FDG in ILD. Here, FOLR2 is linked to interstitial lung disease.